This could be attributed to the distinct mechanisms of anastrozole, which broadly reduces oestrogen levels throughout the body by inhibiting aromatase, in contrast to the more targeted approach of tamoxifen, which focuses on blocking oestrogen receptors in cancer cells and did not exhibit similar patterns, showing a tendency towards a reduction in agalactosylation and increase in sialylation. This evidence concerns the gene CYP19A1 and cancer.